Mozaffar Aznab1, Omid Beiki2,3, Kiumars Eslam Pia4, Khosro Setayeshi4, Mohamad Ali Hesami4, Houshang Vrae4. 1. Talaghani & Imam Reza Hospital, Kermanshah University of Medical Sciences, Kermanshah, Iran. draznab@yahoo.com. 2. Kermanshah University of Medical Sciences, Kermanshah, Iran. 3. Karolinska Institutet, Tomtebodavägen 18A, Floor 5, 171 77, Stockholm, Sweden. 4. Imam Reza Hospital, Kermanshah University of Medical Sciences, Shahid Beheshti BLND, Kermanshah, 6714415333, Iran.
Abstract
AIM: Our aim was to evaluate impact of chemotherapy (5-fluorouracil plus docetaxel and cisplatin) on the survival of gastric cancer cases. METHOD: Seventy-nine patients were eligible to take part in this study between November 2006 and April 2013, who received 5-fluorouracil (700 mg/m2, 21-h infusion within 5 days), cisplatin (60 mg/m2 on day 3), and Docetaxel (60 mg/m2 on day 2). Radiotherapy was added to the treatment only in the cases with entire stomach body cancer (positive margin) and with giant ulcer (above 50 mm) in proximal gastric cancer. RESULTS: Twenty-four patients were female and 55 were male. The median age was 54. In this study, 54 % of the tumors were located in the proximal and 46 % in the distal of stomach. Seventy five percent of patients were at stage I-III (adjuvant chemotherapy), and 25 % at stage IV (palliative chemotherapy). Ninety-one percent of the patients at stages I-II, 68.3 % of the patients at stage III, and one out of 20 patients at stage IV were alive at the end of follow-up. Median disease-free survival for the patients at stages I-III was 63 months, and the overall survival for all patients was 50 months. CONCLUSION: The results of our study indicate that the survival of the patients with stomach cancer increases with chemotherapy. Radiotherapy was used for our patients with gastric cancer in specific cases.
AIM: Our aim was to evaluate impact of chemotherapy (5-fluorouracil plus docetaxel and cisplatin) on the survival of gastric cancer cases. METHOD: Seventy-nine patients were eligible to take part in this study between November 2006 and April 2013, who received 5-fluorouracil (700 mg/m2, 21-h infusion within 5 days), cisplatin (60 mg/m2 on day 3), and Docetaxel (60 mg/m2 on day 2). Radiotherapy was added to the treatment only in the cases with entire stomach body cancer (positive margin) and with giant ulcer (above 50 mm) in proximal gastric cancer. RESULTS: Twenty-four patients were female and 55 were male. The median age was 54. In this study, 54 % of the tumors were located in the proximal and 46 % in the distal of stomach. Seventy five percent of patients were at stage I-III (adjuvant chemotherapy), and 25 % at stage IV (palliative chemotherapy). Ninety-one percent of the patients at stages I-II, 68.3 % of the patients at stage III, and one out of 20 patients at stage IV were alive at the end of follow-up. Median disease-free survival for the patients at stages I-III was 63 months, and the overall survival for all patients was 50 months. CONCLUSION: The results of our study indicate that the survival of the patients with stomach cancer increases with chemotherapy. Radiotherapy was used for our patients with gastric cancer in specific cases.
Authors: Eric Van Cutsem; Vladimir M Moiseyenko; Sergei Tjulandin; Alejandro Majlis; Manuel Constenla; Corrado Boni; Adriano Rodrigues; Miguel Fodor; Yee Chao; Edouard Voznyi; Marie-Laure Risse; Jaffer A Ajani Journal: J Clin Oncol Date: 2006-11-01 Impact factor: 44.544
Authors: K Nakamura; T Ueyama; T Yao; Z X Xuan; K Ambe; Y Adachi; Y Yakeishi; A Matsukuma; M Enjoji Journal: Cancer Date: 1992-09-01 Impact factor: 6.860